{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.295","value":"-0.15"},{"groupId":"OG001","spread":"0.291","value":"-0.58"},{"groupId":"OG002","spread":"0.311","value":"-0.48"}]}],"title":"Change from Baseline at Week 1 [N=63; 64; 57]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.333","value":"-0.36"},{"groupId":"OG001","spread":"0.328","value":"-0.90"},{"groupId":"OG002","spread":"0.347","value":"-1.36"}]}],"title":"Change from Baseline at Week 4 [N=63; 64; 58]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.337","value":"-0.61"},{"groupId":"OG001","spread":"0.333","value":"-1.32"},{"groupId":"OG002","spread":"0.352","value":"-1.41"}]}],"title":"Change from Baseline at Week 8 [N=62; 63; 57]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.322","value":"-0.27"},{"groupId":"OG001","spread":"0.318","value":"-1.33"},{"groupId":"OG002","spread":"0.348","value":"-1.23"}]}],"title":"Change from Baseline at Week 12 [N=62; 63; 54]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.317","value":"-0.31"},{"groupId":"OG001","spread":"0.313","value":"-1.35"},{"groupId":"OG002","spread":"0.331","value":"-1.37"}]}],"title":"Change from Baseline at EOT [N=63; 64; 58]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"A micturition is any voluntary urination, excluding episodes of incontinence only. The mean number of micturitions per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit.\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at baseline \\& 1 or both at any postbaseline on-treatment visit. End of treatment (EOT) includes the last on-treatment assessment for patients who didn't complete Week 12; N is the number of patients included.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 1, 4, 8 and 12","title":"Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Micturitions Per 24 Hours","type":"SECONDARY","unitOfMeasure":"micturitions"}